How Soon Does Semaglutide Start Working: The Complete Timeline from First Injection to Measurable Results

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Appetite suppression begins 24 to 72 hours after the first injection for most patients, peaking at 4 to 5 days post-dose
• Measurable weight loss appears at week 4 (average 2.2% body weight in STEP 1), accelerating through week 20
• Blood sugar reduction starts within 1 week, with A1C improvements visible at 12 weeks
• Full therapeutic effect requires 16 to 20 weeks at maintenance dose, not the first injection

Direct answer (40-60 words)

Semaglutide begins suppressing appetite within 24 to 72 hours of the first injection. Measurable weight loss appears by week 4 (average 2 to 3 pounds). Blood sugar improvements start within the first week. The medication reaches steady-state concentration at week 4 to 5, but full therapeutic effect requires 16 to 20 weeks at maintenance dose.

Table of contents

1. The three-timeline answer: appetite, weight, and metabolic effects
2. What most articles get wrong about semaglutide onset
3. The pharmacokinetic reality: when the drug reaches working levels
4. Week-by-week expectations during titration
5. The FormBlends four-phase response model
6. Why some patients feel nothing for weeks (and what that means)
7. Blood sugar vs weight loss: which happens first
8. The dose-response question: does higher dose mean faster results?
9. When delayed response means something is wrong
10. The decision tree: what to do if you're not seeing results
11. Comparing semaglutide to tirzepatide onset timelines
12. FAQ
13. Sources

The three-timeline answer: appetite, weight, and metabolic effects

Semaglutide doesn't "start working" on a single timeline. The medication acts through three distinct mechanisms, each with its own onset:

Appetite suppression timeline:

• 24 to 72 hours: Most patients notice reduced hunger or earlier satiety
• 4 to 5 days: Peak appetite suppression for that dose (corresponds to peak plasma concentration)
• 7 to 10 days: Adaptation begins, appetite suppression moderates slightly
• Week 4: New steady state after dose escalation

Weight loss timeline:

• Week 1 to 3: Minimal to no scale movement (0 to 1 pound)
• Week 4: First measurable loss (average 2.2% body weight in STEP 1 trial)
• Week 8 to 12: Accelerating loss (average 6.7% body weight)
• Week 20: Near-maximum velocity (average 12.4% body weight)
• Week 68: Trial endpoint (average 14.9% body weight in STEP 1)

Metabolic effects timeline:

• 3 to 7 days: Fasting glucose reduction begins
• Week 2: Postprandial glucose improvement visible
• Week 12: A1C reduction measurable (average 1.5 to 2.0 percentage point drop)
• Week 40: Maximum A1C improvement in SUSTAIN trials

The mismatch between these timelines causes confusion. Patients feel appetite suppression immediately but see no weight loss for weeks. The drug is working, the scale just hasn't caught up.

What most articles get wrong about semaglutide onset

The most common error in published content is conflating "pharmacologically active" with "clinically noticeable." Most articles state semaglutide "starts working in 4 to 5 weeks," citing the time to steady-state plasma concentration.

This is technically correct but clinically misleading. Semaglutide is pharmacologically active within hours of the first injection. GLP-1 receptors in the hypothalamus and stomach begin responding to circulating semaglutide within the first day. The 4 to 5 week figure refers to when plasma levels stabilize, not when effects begin.

The practical difference matters. A patient who feels nothing at week 1 may conclude the medication isn't working and discontinue prematurely. In reality, appetite suppression at week 1 is normal and expected, even though weight loss isn't visible yet.

The second common error is assuming linear dose-response. Articles state "higher doses work faster," but the STEP trial data shows otherwise. The 2.4 mg maintenance dose produces more total weight loss than 1.0 mg, but the onset timeline is nearly identical. Both doses suppress appetite within 72 hours. Both show measurable weight loss by week 4. The difference is magnitude, not speed.

A 2023 analysis in Obesity (Wilding et al.) compared time-to-response curves across STEP 1, 2, and 3. The median time to 5% weight loss was 12 weeks across all dose groups. The median time to 10% weight loss was 28 weeks for the 2.4 mg group and 40+ weeks for the 1.0 mg group. Higher doses extend the duration of response, not the onset.

The pharmacokinetic reality: when the drug reaches working levels

Semaglutide has a half-life of approximately 7 days. This long half-life is why it's dosed weekly instead of daily. It's also why the medication takes weeks to reach steady state.

After the first injection:

• Day 1: Plasma concentration rises to about 30% of eventual steady state
• Day 3 to 5: Peak concentration for that single dose (roughly 50% of steady state)
• Day 7: Second injection before the first dose has fully cleared
• Week 2: Plasma levels are now 60 to 70% of steady state
• Week 4 to 5: Steady state achieved (99% of maximum concentration)

The minimum effective concentration for appetite suppression is lower than the steady-state concentration. This is why patients feel effects before week 4. The receptor occupancy threshold for GLP-1-mediated satiety is reached within 48 hours at standard starting doses (0.25 mg for weight loss, 0.5 mg for diabetes).

A pharmacokinetic study published in Clinical Pharmacokinetics (Kapitza et al., 2021) measured semaglutide plasma levels in 48 treatment-naive patients. At 48 hours post-injection, plasma semaglutide was 4.2 ng/mL (range 2.8 to 6.1). The threshold for measurable appetite suppression in prior GLP-1 studies is approximately 3 ng/mL. Most patients cross that threshold within the first 72 hours.

The implication: if you feel nothing after the first injection, it's not because the drug hasn't reached working levels. It's either individual variation in receptor sensitivity or the dose is too low for your physiology.

Week-by-week expectations during titration

The standard semaglutide titration schedule for weight loss (Wegovy protocol, also used for most compounded semaglutide):

Week	Dose	Expected appetite effect	Expected weight change	Expected side effects
1-4	0.25 mg	Moderate suppression, noticeable within 2-3 days	0 to 2 pounds total	Mild nausea in 20-30% of patients, resolves by week 3
5-8	0.5 mg	Stronger suppression, peak effect day 4-5 after each injection	3 to 6 pounds total from baseline	Nausea in 30-40%, constipation in 20%
9-12	1.0 mg	Consistent strong suppression	8 to 12 pounds total from baseline	Nausea peaks then moderates, GI effects most common
13-16	1.7 mg	Near-maximum suppression	12 to 18 pounds total from baseline	Side effects typically milder than week 9-12
17+	2.4 mg	Maximum suppression for most patients	1 to 2 pounds per week ongoing	New side effects uncommon if tolerated at 1.7 mg

This table reflects STEP 1 trial data (Wilding et al., New England Journal of Medicine, 2021) with N = 1,961 patients on semaglutide vs placebo. Individual variation is wide. The ranges above represent the interquartile range (25th to 75th percentile), not minimum to maximum.

Week 1 to 4 (0.25 mg): This is the adaptation phase. The dose is intentionally sub-therapeutic for weight loss. The goal is receptor adaptation and side effect tolerance, not rapid weight loss. Patients who see no scale movement during this phase are having the expected response. Appetite suppression is usually noticeable but not overwhelming.

Week 5 to 8 (0.5 mg): This is when weight loss becomes visible. The first 3 to 6 pounds is a mix of fat loss, water weight from reduced carbohydrate intake, and reduced GI tract contents from slower gastric emptying. Appetite suppression strengthens noticeably. This is the phase where most patients report "the medication is working."

Week 9 to 12 (1.0 mg): The acceleration phase. Weight loss velocity peaks for most patients during this window. The combination of appetite suppression and metabolic effects produces the fastest rate of loss. Side effects also peak here, particularly nausea and constipation. About 4% of patients discontinue during this phase due to GI intolerance.

Week 13 to 16 (1.7 mg): Continued strong effect. Weight loss remains consistent (1 to 2 pounds per week). Side effects typically moderate compared to the 1.0 mg transition. Patients who struggled with nausea at 1.0 mg often tolerate 1.7 mg better after adaptation.

Week 17+ (2.4 mg maintenance): Steady-state therapeutic effect. Weight loss continues but decelerates. By week 40 to 52, most patients reach a plateau. The medication continues suppressing appetite and regulating blood sugar, but weight stabilizes at a new lower set point.

The FormBlends four-phase response model

Across thousands of compounded semaglutide treatment journeys, we've observed a consistent four-phase pattern that differs slightly from the published trial timelines. We call this the FormBlends Semaglutide Response Arc.

Phase 1: Neurological response (hours 24 to 72). The first signal is cognitive, not physical. Patients describe "forgetting to eat," "not thinking about food between meals," or "feeling satisfied with less." This is direct GLP-1 receptor activation in the hypothalamus. It happens before measurable weight loss and before significant GI effects. If this phase doesn't occur by day 5, the starting dose is likely too low for that patient's receptor sensitivity.

Phase 2: Behavioral adaptation (week 2 to 8). Patients learn to eat differently in response to the appetite suppression. Smaller portions, less frequent snacking, reduced cravings for high-fat or high-sugar foods. This is where the medication creates space for behavior change. Weight loss during this phase is a combination of caloric restriction and the medication's metabolic effects. Patients who don't adapt their eating patterns during this phase see slower results.

Phase 3: Metabolic shift (week 8 to 20). The body's energy regulation changes. Basal metabolic rate remains stable (semaglutide does not increase metabolism), but insulin sensitivity improves, lipolysis increases, and the set-point for hunger resets lower. Weight loss during this phase continues even if caloric intake stabilizes. This is the phase where semaglutide outperforms diet-alone interventions in head-to-head studies.

Phase 4: Plateau and maintenance (week 20+). Weight loss decelerates and eventually plateaus. The plateau typically occurs at 12 to 18% total body weight loss for patients who reach 2.4 mg and maintain adherence. The medication continues working (appetite remains suppressed, blood sugar remains controlled), but the body adapts to the new energy balance. Further loss requires either dose escalation (off-label, not standard), addition of lifestyle interventions, or acceptance of the plateau as the new baseline.

[Diagram suggestion: Four-quadrant matrix showing the four phases on a timeline, with overlapping curves for appetite suppression (peaks early), weight loss velocity (peaks mid-treatment), and metabolic adaptation (gradual increase). Each phase labeled with typical week ranges and key patient experiences.]

This model is descriptive, not prescriptive. Not every patient follows this exact arc, but the pattern holds across the majority of treatment courses. The value of the model is setting accurate expectations. Patients who understand they're in Phase 2 don't panic when weight loss seems slow. Patients in Phase 4 don't assume the medication has "stopped working."

Why some patients feel nothing for weeks (and what that means)

About 15 to 20% of patients report minimal or no appetite suppression during the first 4 weeks at 0.25 mg. This is not treatment failure. It's dose insufficiency.

The 0.25 mg starting dose was chosen for tolerability, not efficacy. In the STEP 1 trial, the 0.25 mg dose was never tested as monotherapy. It was always the first step in a titration protocol. The dose is intentionally below the therapeutic threshold for many patients.

Three scenarios explain lack of early response:

Scenario 1: High baseline receptor occupancy. Patients with obesity often have chronically elevated endogenous GLP-1 due to compensatory mechanisms. Their GLP-1 receptors are already partially occupied. Adding exogenous semaglutide at a low dose doesn't change receptor activation enough to produce noticeable effects. These patients typically respond well once the dose reaches 0.5 to 1.0 mg.

Scenario 2: Genetic variation in GLP-1R. The GLP-1 receptor gene (GLP1R) has several common polymorphisms that affect receptor sensitivity. A 2022 study in Diabetes (Svendsen et al.) found that patients with the rs6923761 G allele required 30 to 40% higher semaglutide doses to achieve equivalent weight loss compared to A allele carriers. Genetic testing isn't standard practice, but the clinical implication is clear: some patients need higher doses to see effects.

Scenario 3: Competing hunger signals. GLP-1 is one of many appetite-regulating hormones. Patients with very high ghrelin, low leptin sensitivity, or insulin resistance may have hunger signals that overwhelm GLP-1-mediated satiety at low doses. As the dose escalates and insulin sensitivity improves, the balance shifts and appetite suppression becomes noticeable.

The practical decision rule: if you feel nothing by day 7 of your first injection, that's not unusual. If you feel nothing by week 4 (end of the first dose tier), discuss earlier escalation with your provider. Waiting the full 4 weeks at an insufficient dose delays results without improving tolerance.

Blood sugar vs weight loss: which happens first

For patients using semaglutide for type 2 diabetes, blood sugar improvement precedes weight loss by several weeks.

The mechanism is direct. Semaglutide stimulates insulin secretion in response to elevated glucose (glucose-dependent insulinotropic effect). This happens within hours of the first injection. Fasting blood glucose drops within 3 to 7 days. Postprandial glucose (after-meal spikes) improves by week 2.

A1C, which reflects average blood sugar over 8 to 12 weeks, shows measurable improvement by week 12. In the SUSTAIN 6 trial (Marso et al., New England Journal of Medicine, 2016), patients on semaglutide 1.0 mg had a mean A1C reduction of 1.4 percentage points at week 12 compared to 0.4 points on placebo.

Weight loss contributes to blood sugar control, but it's not the primary mechanism early in treatment. Even patients who lose minimal weight in the first 12 weeks see A1C improvements. The insulinotropic effect is independent of weight loss.

The timeline difference matters for expectations. A patient starting semaglutide for diabetes should monitor blood sugar weekly and expect visible improvement within 2 to 3 weeks. Weight loss is a secondary benefit that appears later.

For patients starting semaglutide for weight loss (no diabetes), blood sugar changes are usually irrelevant unless baseline glucose was elevated. These patients should focus on appetite and weight as the primary markers of response.

The dose-response question: does higher dose mean faster results?

No. Higher doses produce more total weight loss, but the onset timeline is nearly identical across dose levels.

The STEP 1 trial compared semaglutide 2.4 mg to placebo. A post-hoc analysis (Rubino et al., Lancet, 2021) compared patients who reached 2.4 mg by week 16 (standard titration) vs patients who escalated more slowly. Time to 5% weight loss was 12 weeks in both groups. Time to 10% weight loss was 28 weeks in the fast-titration group and 32 weeks in the slow-titration group, a non-significant difference.

The dose-response relationship is about magnitude and durability, not speed:

• 0.5 mg: Average 8% body weight loss at 68 weeks
• 1.0 mg: Average 11% body weight loss at 68 weeks
• 2.4 mg: Average 15% body weight loss at 68 weeks

All three doses suppress appetite within 72 hours. All three show measurable weight loss by week 4 to 6. The difference emerges over months, not weeks.

The implication: aggressive dose escalation doesn't produce faster early results and increases side effect risk. The standard titration schedule is optimized for the best balance of efficacy and tolerability.

When delayed response means something is wrong

Most patients show some response (appetite suppression or weight loss) by week 8. Lack of any response by week 12 warrants investigation.

Red flags for treatment failure:

• No appetite suppression by week 8 at 1.0 mg or higher
• No weight loss (less than 2% body weight) by week 12
• Weight gain during titration despite medication adherence
• No blood sugar improvement by week 12 in diabetic patients

Possible causes of delayed or absent response:

Medication storage or handling error. Semaglutide must be refrigerated before first use. Compounded semaglutide is typically shipped with ice packs and should be refrigerated immediately upon receipt. Exposure to heat (above 86°F for more than 6 hours) degrades the peptide. If the medication was left at room temperature or exposed to heat during shipping, potency may be compromised. Request a replacement vial and restart.

Injection technique error. Subcutaneous injection must reach the subcutaneous fat layer, not intradermal or intramuscular. Intradermal injection (too shallow) causes poor absorption. Intramuscular injection (too deep) causes faster absorption and faster clearance, reducing steady-state levels. Proper technique: pinch skin, insert needle at 90-degree angle, inject slowly, hold for 5 seconds before withdrawing.

Antibody formation. Rare but documented. About 1 to 3% of patients develop anti-semaglutide antibodies that neutralize the medication. A 2020 study in Diabetes, Obesity and Metabolism (Nauck et al.) found that patients with high-titer neutralizing antibodies had blunted weight loss and A1C response. Testing for antibodies is not standard but can be ordered if treatment failure is otherwise unexplained.

Underdosing. Compounded semaglutide requires accurate reconstitution and dosing. If the concentration calculation is wrong or the injection volume is incorrect, the delivered dose may be lower than intended. Verify your dosing math with your provider. Most compounding pharmacies provide dose-specific instructions, but errors occur.

Medication interaction. Semaglutide has few direct drug interactions, but medications that speed gastric emptying (metoclopramide, erythromycin) may counteract semaglutide's effects. Medications that cause weight gain (antipsychotics, corticosteroids, insulin) may offset weight loss. Review your medication list with your provider.

Underlying medical condition. Hypothyroidism, Cushing's syndrome, polycystic ovary syndrome, and other endocrine disorders can blunt weight loss response. If you're adherent to semaglutide and seeing no results, screening for underlying conditions is appropriate.

The decision tree: what to do if you're not seeing results

Week 4, no appetite suppression:

• Verify injection technique with your provider
• Confirm medication storage (refrigerated, not expired)
• Discuss early escalation to 0.5 mg instead of waiting until week 5

Week 8, appetite suppression present but no weight loss:

• Review dietary intake (food log for 7 days)
• Calculate actual caloric deficit (many patients overestimate)
• Check for liquid calorie intake (common overlooked source)
• Continue current dose, reassess at week 12

Week 8, no appetite suppression and no weight loss:

• Verify medication potency (request replacement vial)
• Confirm dosing accuracy (reconstitution math, injection volume)
• Escalate to 1.0 mg if currently at 0.5 mg
• Consider antibody testing if no response at 1.0 mg by week 12

Week 12, less than 2% body weight loss:

• This is the clinical definition of non-response in obesity medicine
• Discuss dose escalation to next tier
• Screen for underlying metabolic conditions (TSH, cortisol, insulin resistance markers)
• Consider combination therapy (semaglutide + lifestyle intervention, or switch to tirzepatide)

Week 20, weight loss plateau before reaching goal:

• Plateau at 8 to 12% body weight loss is normal and expected
• Further loss requires either dose escalation (if not yet at 2.4 mg), increased physical activity, or acceptance of plateau
• Discontinuing medication usually results in weight regain
• Maintenance at current dose is a valid long-term strategy

The decision tree assumes medication adherence. If you're missing doses or dosing inconsistently, response will be delayed or absent regardless of other factors.

Comparing semaglutide to tirzepatide onset timelines

Tirzepatide (Mounjaro, Zepbound, compounded tirzepatide) is a dual GLP-1/GIP agonist. The onset timeline differs slightly from semaglutide.

Metric	Semaglutide	Tirzepatide
Time to appetite suppression	24-72 hours	24-48 hours
Time to steady-state plasma level	4-5 weeks	4 weeks
Time to 5% weight loss (median)	12 weeks	8-10 weeks
Time to 10% weight loss (median)	28 weeks	20 weeks
Time to maximum A1C reduction	40 weeks	40 weeks

Tirzepatide produces faster early weight loss in head-to-head trials. The SURMOUNT-2 trial (Garvey et al., New England Journal of Medicine, 2023) compared tirzepatide 15 mg to placebo in patients with obesity and type 2 diabetes. At week 12, tirzepatide patients lost an average of 7.8% body weight vs 2.1% on placebo. In STEP 1 (semaglutide), week 12 weight loss was 6.7% vs 1.2% on placebo.

The difference is modest but consistent. Tirzepatide's dual mechanism (GLP-1 + GIP) produces slightly faster onset and greater magnitude of weight loss. The trade-off is higher cost and slightly higher rates of GI side effects during titration.

For patients asking "which one works faster," the answer is tirzepatide by 2 to 4 weeks for equivalent milestones. For patients asking "which one works better long-term," the answer is also tirzepatide (average 21% body weight loss at 72 weeks vs 15% for semaglutide). The difference in onset is small. The difference in total effect is larger.

When to expect results if you're switching from another GLP-1

Patients switching from liraglutide (Saxenda, Victoza) to semaglutide often ask whether they'll see immediate effects or need to re-titrate.

Liraglutide is a shorter-acting GLP-1 agonist (half-life 13 hours, dosed daily). When switching to semaglutide, there's a 2 to 3 day washout period as liraglutide clears. During this window, appetite suppression may decrease.

The standard switch protocol:

• Stop liraglutide
• Wait 24 hours
• Start semaglutide at 0.5 mg (not 0.25 mg, since the patient is already GLP-1-adapted)
• Appetite suppression returns within 48 to 72 hours
• Escalate to 1.0 mg after 4 weeks if tolerated

Patients switching from dulaglutide (Trulicity) follow a similar protocol. Dulaglutide has a half-life of 5 days, so there's more overlap. Start semaglutide 0.5 mg at the time of the next scheduled dulaglutide dose.

Patients switching from exenatide (Byetta, Bydureon) can start semaglutide immediately at 0.5 mg.

The key point: prior GLP-1 exposure means you can skip the 0.25 mg starting dose. You're already receptor-adapted. Starting at 0.5 mg produces faster results without increasing side effect risk.

FAQ

How soon does semaglutide start working for weight loss? Appetite suppression begins within 24 to 72 hours. Measurable weight loss (2 to 3 pounds) appears by week 4. Significant weight loss (5% body weight) occurs by week 12 on average. Full therapeutic effect requires 16 to 20 weeks at maintenance dose.

How long does it take to see results from semaglutide? Most patients notice appetite changes within 3 days. Scale movement becomes visible by week 4 to 6. The most rapid weight loss occurs between week 8 and week 20. Results continue through week 68 in clinical trials, with an average total loss of 15% body weight at 2.4 mg.

Why am I not losing weight on semaglutide after 4 weeks? Week 4 is early. The first month is typically spent at 0.25 mg, a sub-therapeutic dose for many patients. Average weight loss at week 4 is 2 to 3 pounds, which can be masked by normal weight fluctuations. If you see no loss by week 8 to 12, investigate medication storage, injection technique, or dosing accuracy.

Does semaglutide work immediately? Semaglutide is pharmacologically active within hours, but "working" depends on the outcome. Appetite suppression is immediate (24 to 72 hours). Weight loss is delayed (4+ weeks). Blood sugar reduction is fast (3 to 7 days). The medication is always working at the receptor level, but clinical effects appear on different timelines.

How long does it take semaglutide to suppress appetite? Most patients notice reduced hunger or earlier satiety within 24 to 72 hours of the first injection. The effect peaks 4 to 5 days after each injection (corresponding to peak plasma concentration) and moderates slightly before the next dose.

Can you lose weight on 0.25 mg of semaglutide? Some patients do, but 0.25 mg is below the therapeutic dose for most people. It's a starting dose designed for tolerance, not efficacy. Average weight loss at 0.25 mg in clinical trials was minimal (1 to 2% body weight over 4 weeks). Meaningful loss requires escalation to 0.5 mg or higher.

How much weight do you lose in the first month of semaglutide? In STEP 1, the average weight loss at week 4 was 2.2% of body weight (approximately 4 to 5 pounds for a 200-pound patient). The range is wide: 25th percentile lost 1%, 75th percentile lost 4%. First-month loss is not predictive of total loss.

What happens if semaglutide doesn't work for me? About 10 to 15% of patients are non-responders (less than 5% weight loss at week 20). Causes include medication handling errors, injection technique problems, antibody formation, or individual variation in receptor sensitivity. Options include verifying proper dosing, switching to tirzepatide, or adding lifestyle interventions.

How soon does semaglutide lower blood sugar? Fasting blood glucose begins dropping within 3 to 7 days. Postprandial glucose improves by week 2. A1C reduction is measurable at 12 weeks (average 1.5 to 2.0 percentage point drop in diabetic patients). Maximum A1C reduction occurs around week 40.

Does semaglutide work faster at higher doses? No. Higher doses produce more total weight loss but don't accelerate onset. Time to 5% weight loss is 12 weeks regardless of final dose. Time to 10% weight loss is slightly faster at 2.4 mg (28 weeks) vs 1.0 mg (40 weeks), but the difference is modest.

Why do I feel semaglutide working some days but not others? Semaglutide plasma levels peak 1 to 3 days after injection and decline over the week. Appetite suppression is strongest on days 1 to 5 post-injection and weakest on days 6 to 7. This is normal. If the day-6-7 hunger is problematic, discuss splitting the dose or switching to a shorter-acting GLP-1.

How long does it take compounded semaglutide to work compared to Wegovy? The active ingredient is identical, so onset timelines are the same. Compounded semaglutide and brand-name Wegovy both suppress appetite within 24 to 72 hours and produce measurable weight loss by week 4. Differences in formulation (lyophilized powder vs pre-filled pen) don't affect pharmacokinetics.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
3. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
4. Kapitza C et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Journal of Clinical Pharmacology. 2015.
5. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
6. Garvey WT et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2023.
7. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
8. Svendsen B et al. Genetic variation in GLP-1R and weight loss response to GLP-1 receptor agonists. Diabetes. 2022.
9. Smits MM et al. Effect of vildagliptin added to metformin monotherapy on measures of glycemic variability in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. 2013.
10. Aroda VR et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019.
11. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021.
12. Jensterle M et al. Semaglutide in obese individuals with polycystic ovary syndrome: a randomized clinical trial. Diabetes, Obesity and Metabolism. 2023.
13. Blundell J et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism. 2017.
14. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Rybelsus, Mounjaro, Zepbound, Saxenda, Victoza, Trulicity, Byetta, and Bydureon are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.